NovoCure (STU:038) E10: €-0.90 (As of Mar. 2026)


STU:038 NovoCure Ltd STU:038
70 GF Score
Price €13.51
GF Value €16.31
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is NovoCure E10?

NovoCure STU:038 +0.26% 70 E10 is €-0.90 as of Mar. 2026. GuruFocus rates STU:038 with a GF Score™ of 70/100 and a GF Value™ of €16.31 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

NovoCure's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.536. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.90 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-30), NovoCure's current stock price is €13.505. NovoCure's E10 for the quarter that ended in Mar. 2026 was €-0.90. NovoCure's Shiller PE Ratio of today is .


NovoCure  (STU:038) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


NovoCure E10 Related Terms


NovoCure E10 Historical Data

* Premium members only.

The historical data trend for NovoCure's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure E10 Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.05 -0.88

NovoCure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.99 -0.92 -0.90 -0.88 -0.90

STU:038 vs ALMR, UFPT, NEOG: E10 Comparison

For the Medical Devices subindustry, NovoCure's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure Shiller PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NovoCure's Shiller PE Ratio falls into.


STU:038
70GF Score
NovoCure Ltd STU:038
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NovoCure's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.536/330.2130*330.2130
=-0.536

Current CPI (Mar. 2026) = 330.2130.

NovoCure Quarterly Data

per share eps CPI Adj_EPS
201606 -0.427 241.018 -0.585
201609 -0.347 241.428 -0.475
201612 -0.246 241.432 -0.336
201703 -0.196 243.801 -0.265
201706 -0.214 244.955 -0.288
201709 -0.109 246.819 -0.146
201712 -0.101 246.524 -0.135
201803 -0.187 249.554 -0.247
201806 -0.146 251.989 -0.191
201809 -0.111 252.439 -0.145
201812 -0.149 251.233 -0.196
201903 -0.115 254.202 -0.149
201906 -0.009 256.143 -0.012
201909 0.018 256.759 0.023
201912 0.036 256.974 0.046
202003 0.036 258.115 0.046
202006 0.018 257.797 0.023
202009 0.076 260.280 0.096
202012 0.033 260.474 0.042
202103 -0.034 264.877 -0.042
202106 -0.116 271.696 -0.141
202109 -0.111 274.310 -0.134
202112 -0.221 278.802 -0.262
202203 -0.036 287.504 -0.041
202206 -0.218 296.311 -0.243
202209 -0.253 296.808 -0.281
202212 -0.340 296.797 -0.378
202303 -0.467 301.836 -0.511
202306 -0.498 305.109 -0.539
202309 -0.431 307.789 -0.462
202312 -0.413 306.746 -0.445
202403 -0.331 312.332 -0.350
202406 -0.288 314.175 -0.303
202409 -0.252 315.301 -0.264
202412 -0.583 315.605 -0.610
202503 -0.287 319.799 -0.296
202506 -0.312 322.561 -0.319
202509 -0.281 324.800 -0.286
202512 -0.188 324.054 -0.192
202603 -0.536 330.213 -0.536

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.90 mean?
NovoCure (STU:038) has a E10 of €-0.90 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on NovoCure and its competitors.
Is NovoCure's E10 too high?
NovoCure's current E10 is €-0.90. Overall, NovoCure has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's E10 compare to ALMR and UFPT?
NovoCure's E10 of €-0.90 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Devices & Instruments company?
A good E10 depends on the Medical Devices & Instruments industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on NovoCure and its competitors. NovoCure's current E10 is €-0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (STU:038) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.31, compared to a current price of €13.51 — trading 17.2% below its estimated fair value. The current E10 is €-0.90. NovoCure's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For NovoCure (STU:038), the current E10 is €-0.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (STU:038) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of €13.51 is trading 17.2% below its estimated GF Value™ of €16.31. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for STU:038:

  • E10: €-0.90
  • GF Value™: €16.31 vs. price of €13.51 (17.2% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the STU:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
70GF Score

Get the complete analysis for STU:038

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.51
Price
€16.31
GF Value